Researchers randomly assigned 129 patients with previously untreated metastatic uveal melanoma to receive dacarbazine plus selumetinib or placebo.
A variety of viruses are being researched in cancers including melanoma, brain tumors, breast cancers, and others.
The combinatorial approach is not, furthermore, limited to chemotherapy.
Some observational studies suggest that overweight BMI may have a protective effect during cancer treatment.
The management of toxicities and re-initiation of these medications should be made on a case by case basis.
View treatment regimens for melanoma, including guidance on options and dosing for a number of drugs including ipilimumab and dacarbazine.
Two cases raise the question of whether abnormal activation of the hedgehog signaling pathway can lead to a protective effect on melanomas.
The combination may be an attractive option for some, but further research is needed to target the therapy effectively to particular patients.
Baseline tumor size and PD-L1 status were independently associated with the likelihood of a complete response.
The drug combination was studied in patients with BRAFV600E/K mutations in the phase 3 COMBI-AD study, the results of which led to the FDA's Priority Review designation.
It is not always clear whether patients who discontinue anti-PD-1 and -CTLA-4 therapy should re-initiate treatment after adverse events are resolved.
Previous studies have demonstrated that melatonin and its analogues, in addition to their ability to regulate circadian rhythms, may exhibit cytotoxic activity via various cellular mechanisms.
Four hundred and twenty-seven tanning salons were contacted; 32.7% of contacted salons were non-compliant with their respective state's regulations.
Dabrafenib plus trametinib is the first adjuvant therapy indicated specifically for melanoma with the BRAFV600 mutation.
Researchers found that cells resistant to both BRAF inhibition and combination inhibition were sensitive to PAK inhibition, and further that PAK inhibition slowed cell-cycle progression.
Mario Sznol, MD, of the Yale University School of Medicine in New Haven, Connecticut, discusses melanoma clinical trial results just published in the Journal of Clinical Oncology.
Ongoing trials, including those that combine immunotherapy with BRAF inhibitors or a triple combination of an anti-PD-1 antibody with BRAF and MEK inhibitors, may provide more options to patients.
Researchers evaluated data from 7629 patients with melanoma included in the North Carolina cancer registry to determine relevant variables associated with delayed surgery.
Previous studies demonstrated that propranolol may inhibit angiogenesis and migration of cancer cells, leading to a delay in disease progression.
Treatment options for metastatic melanoma are evolving rapidly — creating uncertainties about the best strategies for sequencing targeted and immunotherapeutic agents.
Nicotinamide, a form of vitamin B3 (niacin), may be an effective chemopreventive agent for patients at high risk for developing skin cancer
Investigators randomly assigned 870 patients with advanced melanoma who had undergone complete resection to receive trametinib and dabrafenib vs placebo for 1 year.
The randomized phase 3 CheckMate 238 trial evaluated the safety and efficacy of nivolumab vs ipilimumab in the resected stage III/IV melanoma setting.
CSCC has the second highest mortality rate among skin cancers after melanoma.
Binimetinib a BRAF inhibitor, improved objective response rate (ORR) and progression-free survival (PFS) among patients with BRAF-mutant melanoma.
Clinicians continue to learn about which patients will benefit most from different immunotherapy treatments, and how dosing can effect adverse events.
After the second interim analysis, an external data monitoring committee recommended that pembrolizumab be made available to patients receiving ipilimumab whose disease had progressed despite treatment.
Researchers are evaluating whether 6MHP, a peptide vaccine, is safe and efficacious when combined with ipilimumab in patients with stage IIIB or higher melanoma.
Developments in deep sequencing genomic technologies and bioinformatics have made it possible to identify mutations in melanoma and to predict targetable neoantigens.
The FDA approved the indication expansion for ipilimumab based on evidence from 2 clinical trials evaluating its safety and efficacy in pediatric patients.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy